Insulet price target raised to $43 from $35 at Stephens Stephens raised its price target on Insulet to $43 following the company's Q4 report and FY14 guidance, but says it views the shares as fairly valued and maintains its Equal Weight rating on the stock.
Leerink medical devices analyst holds an analyst/industry conference call Medical Devices Analyst Antalffy assesses the rapidly-evolving diabetes landscape and the potential growth trajectory for Insulet's OmniPod and DexCom's CGM on an Analyst/Industry conference call to be held on January 29 at 2 pm.
Insulet well positioned to beat expectations, says Leerink Leerink believes the worst is now behind Insulet and that the company is positioned for accelerating new patient adds in Q2 and beyond. Leerink thinks lowered base expectations position Insulet to potentially top forecasts in 2015. The firm lowered its price target for shares to $40 and $50 and keeps an Outperform rating on the name.